Related Experiment Video
Updated: Jun 28, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors
Dushyantha T Jayaweera1, Luis Espinoza, Jose Castro
1University of Miami Miller School of Medicine, 1200 NW 195TH Street, Suite 857, Miami, FL 33136, USA. dajayawee@med.miami.edu
Background:
Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations.
Objective:
To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use.
Methods:
The structure and the mechanism of action of etravirine in blocking the reverse transcriptase enzyme and the preclinical, pharmacokinetic and pharmacodynamic studies were reviewed. The DUET Phase III clinical trials and the resistance profile of etravirine were evaluated.
Conclusions:
Etravirine has unique activity against most HIV isolates that are resistant to other NNRTIs. Unlike other NNRTIs, it has a higher genetic barrier to developing high-grade resistance. In the DUET studies, etravirine demonstrated virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are important drug interactions that will need to be taken into consideration with its use.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Retroviruses
Inhibitors Of Virion Release
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes

